Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; and Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:HZNP
Previous Symbol
CUSIP44047T10
Phone011-353-1772-2100
Debt
Debt-to-Equity Ratio2.06
Current Ratio1.94
Quick Ratio1.86
Price-To-Earnings
Trailing P/E Ratio16.85
Forward P/E Ratio15.29
P/E Growth1.29
Sales & Book Value
Annual Sales$1.06 billion
Price / Sales3.16
Cash Flow$3.1014 per share
Price / Cash Flow6.41
Book Value$6.05 per share
Price / Book3.29
Profitability
EPS (Most Recent Fiscal Year)$1.18
Net Income$-410,520,000.00
Net Margins-18.70%
Return on Equity27.14%
Return on Assets6.09%
Miscellaneous
Employees1,010
Outstanding Shares167,630,000
Market Cap$3.28 billion
OptionableOptionable
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma declared that its board has authorized a share repurchase program on Sunday, June 4th 2017, which allows the company to repurchase 1,000% of shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company's management believes its stock is undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) posted its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.15. The biopharmaceutical company earned $325.30 million during the quarter, compared to the consensus estimate of $311.84 million. Horizon Pharma had a negative net margin of 18.70% and a positive return on equity of 27.14%. Horizon Pharma's quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 EPS. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
What guidance has Horizon Pharma issued on next quarter's earnings?
Horizon Pharma updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.17-1.2 billion, compared to the consensus revenue estimate of $1.18 billion.
What price target have analysts set for HZNP?
12 analysts have issued 1-year price targets for Horizon Pharma's stock. Their forecasts range from $18.00 to $35.00. On average, they anticipate Horizon Pharma's stock price to reach $23.6364 in the next twelve months. This suggests a possible upside of 18.9% from the stock's current price. View Analyst Price Targets for Horizon Pharma.
What is the consensus analysts' recommendation for Horizon Pharma?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. Mizuho analysts commented, "We reiterate our Buy rating on Krystexxa momentum and upcoming teprotumumab Phase III data (expected 2Q:19)." (11/7/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for HZNP shares to $23 from $21. The increase in our PT is driven by multiple expansion. We think this is deserved because continued solid execution from the management team underscores our belief that the peak sales potential of HZNP’s orphan/rare disease as well as rheumatology businesses are underappreciated." (10/18/2018)
- 3. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018)
- 4. According to Zacks Investment Research, "Horizon Pharma’s orphan and rheumatology business units witnessed strong growth. We expect Krystexxa, Ravicti and Actimmune to drive further growth. The acquisition of teprotumumab has further diversified the company’s portfolio. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. In June 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in Europe, the Middle East and Africa to Chiesi Farmaceutici S.p.A. to focus on higher return businesses. Shares of the company have outperformed the industry so far this year." (7/17/2018)
Has Horizon Pharma been receiving favorable news coverage?
News headlines about HZNP stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Horizon Pharma earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
Are investors shorting Horizon Pharma?
Horizon Pharma saw a decrease in short interest in November. As of November 30th, there was short interest totalling 7,043,569 shares, a decrease of 22.9% from the November 15th total of 9,137,412 shares. Based on an average daily volume of 1,842,157 shares, the days-to-cover ratio is currently 3.8 days. Currently, 4.2% of the shares of the stock are sold short. View Horizon Pharma's Current Options Chain.
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Bausch Health Companies (BHC), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Alkermes (ALKS), Amarin (AMRN), Catalent (CTLT) and GALAPAGOS NV/S (GLPG).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 51)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 53)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 64)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 48)
- Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 53)
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (8.84%), Vanguard Group Inc. (8.84%), Scopia Capital Management LP (8.81%), BlackRock Inc. (8.18%), William Blair Investment Management LLC (6.32%) and Renaissance Technologies LLC (3.59%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Geoffrey M Curtis, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma.
Which major investors are selling Horizon Pharma stock?
HZNP stock was sold by a variety of institutional investors in the last quarter, including Glenmede Trust Co. NA, JPMorgan Chase & Co., TIAA CREF Investment Management LLC, Dimensional Fund Advisors LP, Capital Fund Management S.A., C WorldWide Group Holding A S, Prudential Financial Inc. and FMR LLC. Company insiders that have sold Horizon Pharma company stock in the last year include Brian K Beeler, Geoffrey M Curtis and Timothy P Walbert. View Insider Buying and Selling for Horizon Pharma.
Which major investors are buying Horizon Pharma stock?
HZNP stock was purchased by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Jennison Associates LLC, Renaissance Technologies LLC, Morgan Stanley, William Blair Investment Management LLC, Vanguard Group Inc, Vanguard Group Inc. and Eagle Asset Management Inc.. View Insider Buying and Selling for Horizon Pharma.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $19.88.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $3.28 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
What is Horizon Pharma's official website?
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
